Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4+ naïve T cells at baseline are associated with severe immune-related adverse events in immune checkpoint inhibitor-treated melanoma
Background Immune-related adverse events (irAEs) are major barriers of clinical management and further development of immune checkpoint inhibitors (ICIs) for cancer therapy. Therefore, biomarkers associated with the onset of severe irAEs are needed. In this study, we aimed to identify immune feature...
Main Authors: | Siwen Hu-Lieskovan, Ngan Nguyen, Magdalena Kovacsovics-Bankowski, John Hyngstrom, Li-Chun Cheng, Jordan P McPherson, Umang Swami, Matthew H Spitzer, Johanna M Sweere, Connor P Healy, Natalia Sigal, William D Chronister, Shane A Evans, John Marsiglio, Berit Gibson, Alyssa Erickson-Wayman, Yoko S Derose, Annaleah Larson Eliason, Carlos O Medina, Ramji Srinivasan |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2024-01-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/12/1/e008056.full |
Similar Items
-
A single center case series of immune checkpoint inhibitor-induced type 1 diabetes mellitus, patterns of disease onset and long-term clinical outcome
by: John Marsiglio, et al.
Published: (2023-08-01) -
Immune Checkpoint Inhibitors in Prostate Cancer
by: Shobi Venkatachalam, et al.
Published: (2021-05-01) -
Immune-Modulating Perspectives for Low Frequency Electromagnetic Fields in Innate Immunity
by: Maria Manuela Rosado, et al.
Published: (2018-03-01) -
Real-world experience with elective discontinuation of PD-1 inhibitors at 1 year in patients with metastatic melanoma
by: Siwen Hu-Lieskovan, et al.
Published: (2021-01-01) -
Real‐world survival of patients with advanced BRAF V600 mutated melanoma treated with front‐line BRAF/MEK inhibitors, anti‐PD‐1 antibodies, or nivolumab/ipilimumab
by: Justin C. Moser, et al.
Published: (2019-12-01)